It's pretty hard going to sell something in medical therapeutic market if you can't show that it has FDA certification and statistically significant proof from a trial that it works. So once the company has that they can market it aggressively. But still progress is likely to be slower using distributors than through employing direct sales staff. And I am hoping that major stakeholders in the company will have a view on how to best promote sales.
Ann: OIL September 2022 Quarterly Report and Appendix 4C, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.010(5.71%) |
Mkt cap ! $137.8M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 16.5¢ | $16.50K | 97.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 168328 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 11.27am 04/10/2024 (20 minute delay) ? |
| OIL (ASX) Chart |